Cline Scientific AB (publ)
Stockholm Stock ExchangeTotal Valuation
Cline Scientific AB (publ) carries a market capitalization of 3.11M, placing it among publicly traded companies globally. Its enterprise value stands at 82.81M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.11M |
| Enterprise Value | 82.81M |
Share Statistics
Cline Scientific AB (publ) currently has 19.06M shares outstanding.
| Shares Outstanding | 19.06M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2,950.94, and the price-to-book ratio stands at -6.06.
| PE Ratio | N/A |
| PS Ratio | 2,950.94 |
| PB Ratio | -6.06 |
| P/TBV Ratio | 10.83 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 2,638.83 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Cline Scientific AB (publ) maintains a current ratio of 14.61, meaning it holds 14.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.61 |
| Quick Ratio | 14.31 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -20.62 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 23.44 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cline Scientific AB (publ)'s stock has declined approximately -68.05556% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | -68.05556% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.08 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cline Scientific AB (publ) generated 31,381.00 in revenue and converted that into -3.07M in net income, yielding earnings per share of -0.18. EBITDA reached -3.05M, while operating income came in at -3.05M.
| Revenue | 31,381.00 |
| Gross Profit | 2.39M |
| Operating Income | -3.05M |
| Pretax Income | -3.07M |
| Net Income | -3.07M |
| EBITDA | -3.05M |
| EBIT | -3.05M |
| Earnings Per Share (EPS) | -0.18 |
Balance Sheet
Total book value stands at -15.28M, with working capital of 9.31M providing operational flexibility.
| Cash & Cash Equivalents | 9.79M |
| Total Debt | N/A |
| Net Debt | -9.79M |
| Equity (Book Value) | -15.28M |
| Book Value Per Share | -0.90 |
| Working Capital | 9.31M |
Margins
Cline Scientific AB (publ) operates with a gross margin of 7,624.13, reflecting its pricing power and cost economics. The operating margin of -9,716.36 and net profit margin of -9,795.42 provide insight into operational efficiency.
| Gross Margin | 7,624.13 |
| Operating Margin | -9,716.36 |
| Pretax Margin | -9,795.42 |
| Profit Margin | -9,795.42 |
| EBITDA Margin | -9,716.36 |
Stock Splits
Cline Scientific AB (publ)'s most recent stock split took place on June 16, 2023 with a 163:201 split ratio.
| Last Split Date | 6/16/2023 |
| Split Ratio | 163:201 |
Scores
Cline Scientific AB (publ) posts an Altman Z-Score of 34.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 34.86 |